Comparative Assessment of Immunological, Hematological, and Serological Profiles in Type 2 Diabetic and Non-Diabetic Patients: A Matched Case-Control Study
DOI:
https://doi.org/10.32792/utq/utjsci/v12i2.1433Keywords:
Intercellular adhesion molecule-1 (ICAM-1), Interleukin-31 (IL-31), Type 2 diabetes mellitusAbstract
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder associated with systemic complications, including hematological and immunological alterations. This study aimed to assess differences in hematological and serological parameters between patients with T2DM and matched non-diabetic controls.
A case-control study with matching was conducted between November 17, 2024, and February 2, 2025, at Smart Health Tower–Raparin, Ranya City. There were 176 participants, with 88 patients with type 2 diabetes mellitus and 88 matched healthy controls. Comparative hematological and biochemical marker measurements between the groups were made using the Mann–Whitney U test. Spearman’s rank correlation was used to estimate the correlation of intercellular adhesion molecule-1 and interleukin-31 with different laboratory markers. The chi-square and Fisher tests were used to compare the frequency distribution of abnormalities in the blood film. A p-value < 0.05 was considered significant.
T2DM patients had significantly higher levels of HbA1c, fasting blood glucose, CRP, ESR, ICAM-1, IL-31, ferritin, total cholesterol, LDL, triglycerides, VLDL, and lower HDL (all p < 0.01). Morphological abnormalities were significantly more frequent among diabetics. IL-31 showed strong positive correlations with HbA1c (r = 0.68), glucose (r = 0.56), CRP (r = 0.45), and ESR (r = 0.30) (all p < 0.01). ICAM-1 was not significantly correlated with other measured parameters.
T2DM is associated with significant hematological and biochemical alterations, including elevated inflammatory markers and abnormal red cell morphology. Regular monitoring of these parameters may aid in the early detection and management of diabetes-related complications.
Received: 2025-07-23
Revised: 2025-11-01
Accepted: 2025-11-29
References
[1] R. Bilous and R. Donnelly, "Handbook of Diabetes," Handbook of Diabetes, 09/15 2010.doi:"10.1002/9781444391374.
[2] N. Elsayed et al., "17. Diabetes Advocacy: Standards of Care in Diabetes—2023," Diabetes Care, vol. 46, pp. S279-S280, 12/12 2022.doi:"10.2337/dc23-S017.
[3] T. Quattrin, L. D. Mastrandrea, and L. S. K. Walker, "Type 1 diabetes," The Lancet, vol. 401, no. 10394, pp. 2149-2162, 2023.doi:"10.1016/S0140-6736(23)00223-4.
[4] V. Nga, L. Anh, D. Dung, N. Minh, L. Hong, and T. Vu, "Applying Logistic Regression to Predict Diabetic Nephropathy Based on Some Clinical and Paraclinical Characteristics of Type 2 Diabetic Patients," VNU Journal of Science: Medical and Pharmaceutical Sciences, vol. 37, 06/28 2021.doi:"10.25073/2588-1132/vnumps.4312.
[5] L. Branchtein et al., "Short stature and gestational diabetes in Brazil," Diabetologia, vol. 43, pp. 848-851, 04/27 2012.doi:"10.1007/s001250051460.
[6] E. Ahmad, S. Lim, R. Lamptey, D. R. Webb, and M. J. Davies, "Type 2 diabetes," The Lancet, vol. 400, no. 10365, pp. 1803-1820, 2022.doi:"https://doi.org/10.1016/S0140-6736(17)30058-2.
[7] E. Młynarska et al., "Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications," International Journal of Molecular Sciences, vol. 26, no. 3. doi: 10.3390/ijms26031094
[8] S.-T. Xu, M. Sun, and Y. Xiang, "Global, regional, and national trends in type 2 diabetes mellitus burden among adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis from the Global Burden of Disease Study 2021," World journal of pediatrics: WJP, vol. 21, 01/03 2025.doi:"10.1007/s12519-024-00861-8.
[9] K. Cromie, R. Murray, R. Ajjan, N. Hughes, R. Feltbower, and A. Glaser, "Diabetes Risk After Treatment for Childhood and Young Adult Cancer," Diabetes care, vol. 48, 01/24 2025.doi:"10.2337/dc24-2171.
[10] W. Chung et al., "Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)," Diabetologia, vol. 63, 09/01 2020.doi:"10.1007/s00125-020-05181-w.
[11] Y. Lu et al., "735-P: Impact of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) on Survival among Cancer Survivors with Type 2 Diabetes," Diabetes, vol. 74, 06/20 2025.doi:"10.2337/db25-735-P.
[12] G. Targher, K. Corey, C. Byrne, and M. Roden, "The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments," Nature Reviews Gastroenterology & Hepatology, vol. 18, pp. 1-14, 05/01 2021.doi:"10.1038/s41575-021-00448-y.
[13] C. Iacobini, M. Vitale, C. Pesce, G. Pugliese, and S. Menini, "Diabetic Complications and Oxidative Stress: A 20-Year Voyage Back in Time and Back to the Future," Antioxidants, vol. 10, p. 727, 05/05 2021.doi:"10.3390/antiox10050727.
[14] M. Arkew, T. Yemane, Y. Mengistu, K. Gemechu, and G. Kiya, "Hematological parameters of type 2 diabetic adult patients at Debre Berhan Referral Hospital, Northeast Ethiopia: A comparative cross-sectional study," PLOS ONE, vol. 16, p. e0253286, 06/14 2021.doi:"10.1371/journal.pone.0253286.
[15] R. Miao, X. Fang, Y. Zhang, J. Wei, Y. Zhang, and J. Tian, "Iron metabolism and ferroptosis in type 2 diabetes mellitus and complications: mechanisms and therapeutic opportunities," Cell Death & Disease, vol. 14, p. 186, 03/01 2023.doi:"10.1038/s41419-023-05708-0.
[16] K. Mohammed, S. Rubat, and A. Imran, "Association of Iron Profile with Type 2 Diabetes Mellitus:Review," International Journal of Pharmaceutical and Bio-Medical Science, vol. 04, pp. 199-205, 03/21 2024.doi:"10.47191/ijpbms/v4-i3-13.
[17] N. Alqahtani, E. Ghazwani, A. Al-Qahtani, and R. Elmahboub, "Correlation of iron levels with glycemia and microvascular complications among type II diabetes mellitus patients in Najran university hospital," Journal of Family Medicine and Primary Care, vol. 11, p. 2690, 06/30 2022.doi:"10.4103/jfmpc.jfmpc_545_21.
[18] H. Saad, H. A. Soliman, B. Mahmoud, A. A. Moneim, and M. Y. Zaky, "The pathogenic role of oxidative stress, cytokine expression, and impaired hematological indices in diabetic cardiovascular diseases," Inflammation, vol. 46, no. 1, pp. 146-160, 2023.doi
[19] H. Ebrahim, T. Fiseha, Y. Ebrahim, and H. Bisetegn, "Comparison of hematological parameters between type 2 diabetes mellitus patients and healthy controls at Dessie comprehensive specialized hospital, Northeast Ethiopia: Comparative cross-sectional study," PLOS ONE, vol. 17, p. e0272145, 07/27 2022.doi:"10.1371/journal.pone.0272145.
[20] D. Abebe, G. Kiya, R. Alemu, and W. Beyene, "Assessment of Hematological Profiles and Prognostic Role of Hemogram-Derived Novel Markers for Diabetes Mellitus and Its Complications Among Type 2 Diabetes Mellitus Adult Patients Attending Bishoftu General Hospital, Central, Ethiopia: A Comparative Cross-Sectional Study," Journal of Blood Medicine, vol. 14, pp. 681-699, 12/27 2023.doi:"10.2147/JBM.S435452.
[21] B. Son, V. Nga, L. Hong, and D. Quynh, "Potent Natural Inhibitors of Alpha-Glucosidase and the Application of Aspergillus spp. in Diabetes type 2 Drugs: a Review," VNU Journal of Science: Medical and Pharmaceutical Sciences, vol. 38, 03/24 2022.doi:"10.25073/2588-1132/vnumps.4334.
[22] M. Hu et al., "Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus," Diabetology & Metabolic Syndrome, vol. 17, no. 1, p. 10, 2025/01/09 2025.doi:"10.1186/s13098-024-01571-x.
[23] R. Vergallo, I.-K. Jang, and F. J. A. Crea, "New prediction tools and treatment for ACS patients with plaque erosion," vol. 318, pp. 45-51, 2021.doi
[24] I. Lempesis and V. Georgakopoulou, "Physiopathological mechanisms related to inflammation in obesity and type 2 diabetes mellitus," World Journal of Experimental Medicine, vol. 13, 06/17 2023.doi:"10.5493/wjem.v13.i3.7.
[25] S. Al-Shammaree, R. Alshawk, and H. Baher, "Intercellular Adhesion Molecule-1, Vascular Adhesion Molecule- 1, Interlukin1-β, and C - reactive protein Levels in Iraqi Patients with Type 2 Diabetes Mellitus," IOSR Journal of Dental and Medical Sciences, vol. 13, pp. 55-62, 01/01 2014.doi:"10.9790/0853-13445562.
[26] S. E. Akar et al., "A multitude of dyes but unsatisfactory staining: Physico-chemical profile and factors associated with staining quality of Romanowsky-type stains used for malaria microscopy in Plateau State, Nigeria," medRxiv, p. 2025.04.07.25325361, 2025.doi:"10.1101/2025.04.07.25325361.
[27] R. Minic and I. Zivkovic, "Optimization, Validation and Standardization of ELISA," 2020.
[28] H. Hussein, A. Alkhuzai, C. Janson, and K. Amin, "A comparative study of multiple biomarkers levels in complicated versus noncomplicated type 2 diabetic patients," Cellular and molecular biology (Noisy-le-Grand, France), vol. 70, pp. 45-52, 04/28 2024.doi:"10.14715/cmb/2024.70.4.8.
[29] G. Hegazy, Z. Awan, E. Hashem, N. Al-Ama, and A. Abunaji, "Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications," Journal of International Medical Research, vol. 48, p. 030006051989385, 12/29 2019.doi:"10.1177/0300060519893858.
[30] C. Turpin, A. Fraiwan, and U. Gurkan, "Novel RBC Adhesion and Deformability Assays Reveal Deleterious Effect of Diabetes on RBC Health," Blood, vol. 142, pp. 1072-1072, 11/28 2023.doi:"10.1182/blood-2023-182036.
[31] D. Milosevic and V. L. Panin, "Relationship Between Hematological Parameters and Glycemic Control in Type 2 Diabetes Mellitus Patients," (in eng), J Med Biochem, vol. 38, no. 2, pp. 164-171, Apr 2019.doi:"10.2478/jomb-2018-0021.
[32] R. A. Abdullah and I. S. Abdulrahman, "Circulating Cell Adhesion Molecules Level in Type 2 Diabetes Mellitus and Its Correlation with Glycemic Control and Metabolic Syndrome: A Case-control Study," vol. 20, no. 1, pp. 64-70, 2023.doi:"10.4103/mjbl.Mjbl_246_22.
[33] H. Bashir et al., "Role of inflammatory mediators (TNF-α, IL-6, CRP), biochemical and hematological parameters in type 2 diabetes mellitus patients of Kashmir, India," (in eng), Med J Islam Repub Iran, vol. 34, p. 5, 2020.doi:"10.34171/mjiri.34.5.
[34] H. Bashir et al., "Inter-relationship of Pro- and Anti- inflammatory Biomarkers with the development of Type 2 Diabetes Mellitus," Heliyon, vol. 8, no. 11, 2022.doi:"10.1016/j.heliyon.2022.e11329.
[35] B. Butt et al., "Enhanced Creatinine Level in Diabetic Patients Maximizing the Possibilities of Nephropathy and Its Association With Blood Urea Nitrogen and Glomerular Filtration Rate," Cureus, vol. 16, 09/30 2024.doi:"10.7759/cureus.70482.
[36] Y. Bi et al., "Association between liver enzymes and type 2 diabetes: a real-world study," Frontiers in Endocrinology, vol. 15, 02/20 2024.doi:"10.3389/fendo.2024.1340604.
[37] D. McClain, C. Usoh, F. Lorenzo, and A. Harrison, "116-LB: Interaction between Iron Stores and Metformin Action," Diabetes, vol. 71, 06/01 2022.doi:"10.2337/db22-116-LB.
[38] I. Kirkutyte and G. O. Latunde-Dada, "Relationship Between Hepatic Iron Concentration and Glycemic Metabolism, Prediabetes, and Type 2 Diabetes: A Systematic Review," Nutrition Reviews, vol. 83, no. 7, pp. e1828-e1842, 2024.doi:"10.1093/nutrit/nuae197 %J Nutrition Reviews.
[39] X. Liu et al., "Epidemiological and transcriptome data identify potential key genes involved in iron overload for type 2 diabetes," Diabetology & Metabolic Syndrome, vol. 15, no. 1, p. 134, 2023/06/21 2023.doi:"10.1186/s13098-023-01110-0.
[40] S. Priya and N. Begum, "Correlation of Lipid Profile with Duration of Diabetes and HbA1c Levels in Type 2 Diabetes Mellitus Patients: A Descriptive Cross-sectional Study," vol. 3, no. 1, pp. 19-22, 2020.doi:"10.5005/jp-journals-10082-02234.
[41] L. Qasem, A. Al-Shami, and A. Al-Olofi, "Evaluation of anthropometric parameters, Liver Enzymes, Albumin, and Lipid Profile Levels in Patients with Type Two Diabetes Mellitus, in Amran City, Yemen," مجلة جامعة عمران, vol. 5, no. 9, 06/30 2025.doi:"10.59145/jaust.v5i9.127.
[42] M. O. Alharbi and A. A. Sulaiman, "Foot care knowledge, attitude and practices of diabetic patients: A survey in Diabetes health care facility," vol. 11, no. 7, pp. 3816-3823, 2022.doi:"10.4103/jfmpc.jfmpc_183_21.
[43] O. A. A. Alareeqi, Y. H. A. Obady, M. Q. Al-Khulaidi, and K. Al-Mureish, "SOME STUDIES ON RED BLOOD CELLS MORPHOLOGY OF HEALTHY AND DIABETIC PATIENTS IN TAIZ, YEMEN," Electronic Journal of University of Aden for Basic and Applied Sciences, vol. 2, no. 3, pp. 109-123, 09/30 2021.doi:"10.47372/ejua-ba.2021.3.105.
[44] R. N. S. Abdulla and S. N. Zangana, "Relationship between Type 2 Diabetes Mellitus and Red Cell Distribution Width," AMJ (Advanced Medical Journal), vol. 9, no. 4, pp. 144-151, 12/01 2024.doi:"10.56056/amj.2024.309.
[45] T. N. Le, R. Bright, V. K. Truong, J. Li, R. Juneja, and K. Vasilev, "Key biomarkers in type 2 diabetes patients: A systematic review," Diabetes, Obesity and Metabolism, vol. 27, pp. 7-22, 10/02 2024.doi:"10.1111/dom.15991.
[46] H. Alrawi, "EVALUATION OF RED BLOOD CELL INDICES IN TYPE 2 DIABETES MELLITUS IN SULAYMANIYAH CITY, KURDISTAN REGION, IRAQ," JOURNAL OF SULAIMANI MEDICAL COLLEGE, vol. 12, pp. 197-206, 06/21 2022.doi:"10.17656/jsmc.10361.
[47] E. Aya Refat and A.-H. Zainab Hussein, "Elevated IL-31 and IL-31RA with Dyslipidemia in T2DM Patients," International Journal of Health Sciences, vol. 6, no. S10, pp. 1-13, 2022 2022.doi:"10.53730/ijhs.v6nS10.13309.
Downloads
Published
License
Copyright (c) 2025 University of Thi-Qar Journal of Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
